Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience reported its 2025 year-end results highlighting a rights issue that raised approximately SEK 91 million before costs to bolster liquidity and support further development of lead cancer drug candidate mitazalimab. The financing, complemented by bridge loans and potential future warrant proceeds, aims to secure the company’s transition of mitazalimab into its next development phase, despite continued operating losses and modest net sales.
The company advanced its scientific and strategic position through new peer-reviewed publications and congress presentations validating mitazalimab and ATOR-4066, and by securing a U.S. patent for ATOR-4066 to reinforce intellectual property and long-term asset value. Partner Shanghai Henlius progressed the HLX22 program into Phase 2/3 breast cancer trials in China, preserving a potential future revenue stream for Alligator via milestones and royalties and underscoring the broader commercial optionality of its portfolio.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.18 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology company focused on developing immuno-oncology therapies. Its primary pipeline includes mitazalimab, a next-generation CD40 agonist antibody, and ATOR-4066, along with partnered asset HLX22, targeting cancer indications and potential global licensing and royalty-driven revenues.
Average Trading Volume: 4,988,595
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK98.52M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.